Antimicrobial Agents and Chemotherapy · 2003 · 400 citations · 43 references
Life SciencesInfectious DiseasesMicrobiologyBacteriologyDiagnostic MicrobiologyMedical MicrobiologyAntibiotic ResistanceBacterial EpidemiologyBacterial InfectionsBeta-lactam ResistanceClinical BacteriologyMedical BacteriologyAntibiotic Resistance In Bloodstream IsolatesBeta-lactamase GenesClass B Metallo-beta-lactamasesExtended-spectrum Beta-lactamase Producing OrganismsExtended-spectrum Beta-lactamase ProductionExtended-spectrum Beta-lactamase-producing OrganismsExtended-spectrum Beta-lactamasesSpectrum Of Beta-lactam Antibiotics
A huge variety of extended-spectrum beta-lactamases (ESBLs) have been detected during the last 20 years. The majority of these have been of the TEM or SHV lineage. We have assessed ESBLs occurring among a collection of 455 bloodstream isolates of Klebsiella pneumoniae, collected from 12 hospitals in seven countries. Multiple beta-lactamases were produced by isolates with phenotypic evidence of ESBL production (mean of 2.7 beta-lactamases per isolate; range, 1 to 5). SHV-type ESBLs were the most common ESBL, occurring in 67.1% (49 of 73) of isolates with phenotypic evidence of ESBL production. In contrast, TEM-type ESBLs (TEM-10 type, -12 type, -26 type, and -63 type) were found in just 16.4% (12 of 73) of isolates. The finding of TEM-10 type and TEM-12 type represents the first detection of a TEM-type ESBL in South America. PER (for Pseudomonas extended resistance)-type beta-lactamases were detected in five of the nine isolates from Turkey and were found with SHV-2-type and SHV-5-type ESBLs in two of the isolates. CTX-M-type ESBLs (bla(CTX-M-2) type and bla(CTX-M-3) type) were found in 23.3% (17 of 73) of isolates and were found in all study countries except for the United States. We also detected CTX-M-type ESBLs in four countries where they have previously not been described-Australia, Belgium, Turkey, and South Africa. The widespread emergence and proliferation of CTX-M-type ESBLs is particularly noteworthy and may have important implications for clinical microbiology laboratories and for physicians treating patients with serious K. pneumoniae infections.
43
David L. Paterson, José María Casellas, Wen‐Chien Ko et al. · Clinical Infectious Diseases · 2000 · 385 citations · Full text
D. Sirot, J. Sirot, Roger Labia et al. · Journal of Antimicrobial Chemotherapy · 1987 · 357 citations